cd4+/cd25+ cells
JMML
Masonic Cancer Center, University of MinnesotaCell therapyN/ADormant
D
30/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 15/ 100
- Competitive Position
- 95/ 100
Competitive context
0 Active assets in the JMML cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Equine Atg St. Jude Children's Research Hospital | Phase 3 | B |
cd4+ t cells Masonic Cancer Center, University of Minnesota | N/A | D |
Same molecule, other indications
cd4+/cd25+ cells is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →